BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jewett A. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions. Front Immunol 2020;11:1692. [PMID: 32754162 DOI: 10.3389/fimmu.2020.01692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Lehmann AA, Kirchenbaum GA, Zhang T, Reche PA, Lehmann PV. Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity. Front Immunol 2021;12:635942. [PMID: 34127926 DOI: 10.3389/fimmu.2021.635942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ameratunga R, Woon ST, Steele R, Snell R, Medlicott N, Mears E, Leung E, Lehnert K, Jordan A, Das S, Abbott W, Longhurst H, Quiñones-Mateu ME. Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. Expert Rev Clin Immunol 2021;17:553-60. [PMID: 33792473 DOI: 10.1080/1744666X.2021.1912596] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhao R, Sun Y, Zhang Y, Wang W, Wang S, Wang C, Liu J, Gao L, Hu Z, Fei J, Hou X, Zheng H, Chen L. Distinguishable Immunologic Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic Individuals. Mediators Inflamm 2020;2020:6914878. [PMID: 33061829 DOI: 10.1155/2020/6914878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Diallo A, Pichelin M, Wargny M, Gourdy P, Bonnet JB, Hadjadj S, Cariou B, Sultan A, Galtier F; CORONADO investigators. Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study. Diabetes Obes Metab 2021. [PMID: 34658131 DOI: 10.1111/dom.14577] [Reference Citation Analysis]
5 Jiménez-Cortegana C, Liró J, Palazón-Carrión N, Salamanca E, Sojo-Dorado J, de la Cruz-Merino L, Pascual Á, Rodríguez-Baño J, Sánchez-Margalet V. Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. Viral Immunol 2021;34:639-45. [PMID: 34529510 DOI: 10.1089/vim.2021.0044] [Reference Citation Analysis]
6 Taghioff SM, Slavin BR, Holton T, Singh D. Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients. PLoS One 2021;16:e0255541. [PMID: 34343191 DOI: 10.1371/journal.pone.0255541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Marik PE, Iglesias J, Varon J, Kory P. A scoping review of the pathophysiology of COVID-19. Int J Immunopathol Pharmacol 2021;35:20587384211048026. [PMID: 34569339 DOI: 10.1177/20587384211048026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. Cells 2020;9:E1975. [PMID: 32859121 DOI: 10.3390/cells9091975] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
9 Stoy N. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front Immunol 2021;12:638446. [PMID: 33936053 DOI: 10.3389/fimmu.2021.638446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yeo JG, Leong JY, Tay SH, Nadua KD, Anderson DE, Lim AJM, Ng XW, Poh SL, Guo D, Yaung KN, Kumar P, Wasser M, Hazirah SN, Sutamam N, Chua CJH, Qui M, Foo R, Gamage AM, Yeo KT, Ramakrishna L, Arkachaisri T, Young BE, Lye DC, Wang LF, Chong CY, Tan NWH, Li J, Kam KQ, Ginhoux F, Thoon KC, Chan JKY, Yung CF, Albani S. A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19. Front Immunol 2021;12:674279. [PMID: 34113347 DOI: 10.3389/fimmu.2021.674279] [Reference Citation Analysis]
11 Deng X, Terunuma H, Nieda M. Exploring the Utility of NK Cells in COVID-19. Biomedicines 2022;10:1002. [DOI: 10.3390/biomedicines10051002] [Reference Citation Analysis]
12 Schiuma G, Beltrami S, Bortolotti D, Rizzo S, Rizzo R. Innate Immune Response in SARS-CoV-2 Infection. Microorganisms 2022;10:501. [DOI: 10.3390/microorganisms10030501] [Reference Citation Analysis]
13 Kim H, Byun JE, Yoon SR, Koohy H, Jung H, Choi I. SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity. Cell Immunol 2021;371:104454. [PMID: 34773897 DOI: 10.1016/j.cellimm.2021.104454] [Reference Citation Analysis]